1. Introduction {#sec1-pharmaceuticals-12-00034}
===============

The *Asteraceae* (*Compositae*) family is known for its therapeutic, cosmetic and aromatic properties. Its main uses are anthelmintic, anti-inflammatory, astringent, cholesteric, anti-hemorrhagic, antimicrobial, antioxidant, diuretics, analgesics and antispasmodics \[[@B1-pharmaceuticals-12-00034],[@B2-pharmaceuticals-12-00034],[@B3-pharmaceuticals-12-00034],[@B4-pharmaceuticals-12-00034],[@B5-pharmaceuticals-12-00034]\].

Among the species of this family stands the *Tithonia diversifolia*, popularly known as Margaridão, the Amazonian flower, and the Mexican sunflower. Although this species is native to Mexico, it can already be found in different regions of Brazil and Africa \[[@B6-pharmaceuticals-12-00034]\].

In West Africa, leaf alcohol extracts are widely used for the treatment of chronic malaria, an alternative utilized by the low-income population that suffers from a high mortality rate of this disease, especially among children \[[@B7-pharmaceuticals-12-00034]\].

Many studies carried out to prove the biological activities of this species are limited in studies with crude extracts, mostly ethanolic extracts. Little is known about the biological activities that the essential oils of *T. diversifolia* can provide for the treatment of different diseases described by ethnopharmacology \[[@B8-pharmaceuticals-12-00034]\] such as constipation, stomach pains, indigestion, sore throat, liver pain, menstrual pain \[[@B9-pharmaceuticals-12-00034]\], anti-inflammatory activities \[[@B10-pharmaceuticals-12-00034]\], anticancer activity \[[@B11-pharmaceuticals-12-00034]\], anti-amoebic \[[@B12-pharmaceuticals-12-00034]\], antiviral and activity against the human immunodeficiency virus \[[@B13-pharmaceuticals-12-00034]\].

In addition, there is little research in Brazil that proves the biological activities of the essential oil of this species. In relation to the state of Amapá, which is considered the most conserved territory of the Brazilian Amazon \[[@B14-pharmaceuticals-12-00034]\], the results obtained in this work are unpublished. Thus, the objective of this study was to evaluate the chemical composition, antioxidant, cytotoxic and microbiological activity of the essential oil of the leaves of the species *T. diversifolia* (*Asteraceae*).

2. Results {#sec2-pharmaceuticals-12-00034}
==========

2.1. Chemical Characterization of Essential Oil {#sec2dot1-pharmaceuticals-12-00034}
-----------------------------------------------

The essential oil yield of *T. diversifolia* leaves, obtained by hydrodistillation, was 0.65% (m/m). The chemical composition can be observed in [Table 1](#pharmaceuticals-12-00034-t001){ref-type="table"}. The main constituents ([Figure S8](#app1-pharmaceuticals-12-00034){ref-type="app"}) are *α*-pinene (9.9%), Limonene (5.40%), *(Z)-β*-ocimene (4.02%), *p*-cymen-8-ol (3.0%), Piperitone (11.72%), *(E)*-nerolidol (3.78%) and Spathulenol (10.8%).

For the confirmation of the major substances, *T. diversifolia* essential oil was analyzed by 1H and 13C NMR ([Figure S8](#app1-pharmaceuticals-12-00034){ref-type="app"}) described in [Table 2](#pharmaceuticals-12-00034-t002){ref-type="table"}, [Table 3](#pharmaceuticals-12-00034-t003){ref-type="table"}, [Table 4](#pharmaceuticals-12-00034-t004){ref-type="table"}, [Table 5](#pharmaceuticals-12-00034-t005){ref-type="table"}, [Table 6](#pharmaceuticals-12-00034-t006){ref-type="table"}, [Table 7](#pharmaceuticals-12-00034-t007){ref-type="table"}, [Table 8](#pharmaceuticals-12-00034-t008){ref-type="table"} and [Table 9](#pharmaceuticals-12-00034-t009){ref-type="table"}.

The 1 H-NMR spectrum ([Figure S1](#app1-pharmaceuticals-12-00034){ref-type="app"}) was absorbed from the essential oil of *T. diversifolia*, this being a mixture of compounds, where differences in the intensities of the overlap signals can be observed.

2.2. Antioxidant Activity {#sec2dot2-pharmaceuticals-12-00034}
-------------------------

The values obtained of the antioxidant activity %AA of the essential oil of the species *T. diversifolia* can be observed in [Table 10](#pharmaceuticals-12-00034-t010){ref-type="table"}: The values obtained of the antioxidant activity %AA of the essential oil of the species *T. diversifolia* can be observed in [Table 10](#pharmaceuticals-12-00034-t010){ref-type="table"}:

Horizontally, % AA values followed by the same letter did not present significant differences for ANOVA (*p* \< 0.05).

The essential oil extracted from the leaves of *T. diversifolia* showed significant antioxidant activity and significant value with *p* \< 0.0001 at the concentration of 5 mg·mL^−1^ with %AA 54.6 ± 0.06. The minimum inhibitory concentration (IC~50~) was 4.30 mg·mL^−1^, with a strong correlation coefficient (R^2^) of 0.9965.

To evaluate the antioxidant potential the essential oil of *T. diversifolia* was used as an antioxidant standard constituent ascorbic acid. To achieve this, an assay was performed using the 2,2-diphenyl-1-picrylhydrazyl (DPPH)free radical consumption method ([Table 11](#pharmaceuticals-12-00034-t011){ref-type="table"}).

The values obtained indicated that compared with this standard (ascorbic acid), the essential oil of *T. diversifolia* had low antioxidant activity. The IC50 of ascorbic acid had an IC 50 of 16.71 μg·mL^−1^, a much lower value than that of essential oil, which was 4.30 mg·mL^−1^.

2.3. Cytotoxicity Test {#sec2dot3-pharmaceuticals-12-00034}
----------------------

[Table 12](#pharmaceuticals-12-00034-t012){ref-type="table"} shows the readings performed and the calculations of mean mortality performed within 48 h of the cytotoxic activity of *T. diversifolia* essential oil against nauplii (*A. salina* larvae). The results are significant and are expressed as percent mortality (%).

Values with equal superscript letters represent significant equality in the concentrations of essential oils.

The essential oil of *T. diversifolia* presented LC~50~ of 3.11 μg·mL^−1^ and correlation coefficient of R2 0.999, evidencing high toxicity against larvae of *A. salina*.

2.4. Antimicrobial Activity {#sec2dot4-pharmaceuticals-12-00034}
---------------------------

[Table 13](#pharmaceuticals-12-00034-t013){ref-type="table"} shows the results corresponding to the minimum concentrations for inhibition of the growth of bacteria *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*.

3. Discussion {#sec3-pharmaceuticals-12-00034}
=============

3.1. Chemical Characterization of Essential Oil {#sec3dot1-pharmaceuticals-12-00034}
-----------------------------------------------

The results of the chemical composition of the essential oil of leaves of the vegetal species of this study corroborate with the results of the research done by Lawal et al. \[[@B24-pharmaceuticals-12-00034]\], which is similar in composition to that found in this study.

3.2. Antioxidant Activity {#sec3dot2-pharmaceuticals-12-00034}
-------------------------

The antioxidant activity was performed by the DPPH radical capture method (or DPPH consumption). This methodology consists of absorbance reading through a Spectrophotometer, the higher the absorbance values, the greater the antioxidant activity. The determination of the antioxidant activity was carried out using the DPPH free radical capture method, however, it is known that the essential oils are complex mixtures and it is difficult to attribute certain biological activities. In the present assay, the elimination of the radical was shown to be low. The aspect presented was still slightly purple. The antioxidant activity is directly related to the free radical consumption. The higher this consumption, the greater the activity and the lower the inhibitory concentration, in this case the IC 50 \[[@B25-pharmaceuticals-12-00034],[@B26-pharmaceuticals-12-00034],[@B27-pharmaceuticals-12-00034]\].

The antioxidant activity is related to the ability of a substance to eliminate free radicals; the radicals with this arrangement have unpaired electrons in their last electronic layer, making the compound highly unstable and reactive. Substances that have the ability to reduce oxidative stress caused by excessive oxidation can protect a biological system from different pathologies such as diabetes mellitus, multiple sclerosis, heart disease, Parkinson's disease, inflammation, Alzheimer's disease, atherosclerosis, stroke, and cancer \[[@B28-pharmaceuticals-12-00034]\].

According to Oliveira \[[@B29-pharmaceuticals-12-00034]\], the method of reducing or neutralizing the stable free radical, DPPH, can assess the antioxidant capacity of various substances. DPPH is widely used for this purpose due to its efficiency, practicality, and speed.

The presence of spathulenol (10.8%) as one of the major compounds of *T. diversifolia* essential oil may explain the antioxidant activity observed in this study. This result corroborates with research by Ćavar et al. \[[@B30-pharmaceuticals-12-00034]\] that verified a high presence of spathulenol and attributed this to the significant antioxidant activity verified in the oils of the species *Satureja montana* L.

Researchers conducted by Roberto et al. \[[@B31-pharmaceuticals-12-00034]\] and Seol \[[@B32-pharmaceuticals-12-00034]\] also observed the antioxidant activity of limonene and linalool compounds, noting that they act as regulators of oxidative stress. It is observed the presence of these substances in the chemical composition of the essential oil of *T. diversifolia* (limonene 5.40% and linalool 0.32%), which could justify the results obtained for this activity.

3.3. Cytotoxicity Test {#sec3dot3-pharmaceuticals-12-00034}
----------------------

The larvae of *A. salina* (nauplii), are effective to verify if a certain plant sample is toxic. A preliminary toxicity test on plant species is important to verify that the study material may contain substances that cause damage to the health of a population. In addition, toxicity results may point to the possibility that the test material (*T. diversifolia* essential oil) may be used for biocidal, repellent and antitumor activities \[[@B33-pharmaceuticals-12-00034],[@B34-pharmaceuticals-12-00034],[@B35-pharmaceuticals-12-00034]\].

Studies performed by Silva et al. \[[@B36-pharmaceuticals-12-00034]\] and Eltayeib and Ishag \[[@B37-pharmaceuticals-12-00034]\], classify the toxicity of the plant as follows: values less than 100 μg·mL^−1^ are considered highly toxic, above 100 μg·mL^−1^ the classification considers them to be moderate, values greater than 500 μg·mL^−1^ are of low toxicity, and values with LD~50~ above 1000 μg·mL^−1^ are classified as non-toxic. In this way, the *T. diversifolia* oil can be classified as highly toxic.

According to Riani et al. \[[@B38-pharmaceuticals-12-00034]\], the presence of piperitone in the chemical constitution of a species can make it toxic. In the same way, supporting the results obtained in this study, since the present chemical constituent is one of the main identified compounds of the species of study.

The World Health Organization conceptualizes medicinal plants as being species that have in some part of their organism the presence of chemical compounds that can be used for therapeutic purposes. In this sense, it is imperative that studies are conducted to evaluate the benefits that herbal medicines can provide. However, it is observed that certain species of plants have in their chemical composition substances that can be considered potentially harmful when not used correctly \[[@B39-pharmaceuticals-12-00034]\].

Studies performed by Passoni et al. \[[@B40-pharmaceuticals-12-00034]\] observed a high degree of toxicity in the crude aqueous extract obtained from the leaves of *T. diversifolia*, against Wistar rats, from repeated doses of the extract of the species. However, biological losses were observed only at high doses, above 100 mg·mL^−1^.

3.4. Antimicrobial Activity {#sec3dot4-pharmaceuticals-12-00034}
---------------------------

The results of this research corroborate with data verified by Linthoingambi and Mutum \[[@B41-pharmaceuticals-12-00034]\], which report the use of organic extracts (petroleum ether, chloroform, and methanol) obtained from the leaves of *T. diversifolia*, perceiving the inhibitory action of growth against bacteria *Enterococcus faecalis*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

The bacterium *E. coli* (ATCC 8739), although part of the intestinal tract, stands out as being widely used for antimicrobial formulation.

However, beings with low immunity make it possible to increase the concentration, which in turn leads to an infection. To this end, the continued use of products known for this treatment has generated mutations and increased resistance of the bacteria. Thus, essential oils with bactericidal potential may be a promising alternative for this problem. In this case, antibiotic treatment becomes necessary \[[@B42-pharmaceuticals-12-00034],[@B43-pharmaceuticals-12-00034],[@B44-pharmaceuticals-12-00034],[@B45-pharmaceuticals-12-00034]\].

For Vahdani et al. \[[@B46-pharmaceuticals-12-00034]\] essential oils that have piperitone in its composition have bacterial action, which would justify the strong inhibitory action exhibited by the essential oil of *T. diversifolia*, since the substance was the most abundant in the chemical composition of the oil, presenting a percentage of 11.72%.

Odeyemi et al. \[[@B47-pharmaceuticals-12-00034]\] emphasize the use of *T. diversifolia* crude extracts in methanol, ethanol, and water as promising antibacterial agents since they had antimicrobial effects on *P. aeruginosa*, *Shigella spp*, *Enterococcus spp*, *E. coli* and *Salmonella spp*. However, few studies have described the action of essential oils of *T. diversifolia* against pathogens.

For Guinoiseau et al. \[[@B48-pharmaceuticals-12-00034]\], the use of essential oils may be more efficient as antimicrobial substances, because their characteristics contribute to the weakening of the cell wall of the bacterium, which could potentiate the antimicrobial activity of *T. diversifolia* species.

4. Material and Methods {#sec4-pharmaceuticals-12-00034}
=======================

4.1. Collection of Plant Material {#sec4dot1-pharmaceuticals-12-00034}
---------------------------------

The species was collected in the district of Fazendinha-AP, under the coordinates 0°1'17.59" S and 51°6'17.59" W, and later it was sent to the Herbarium of the Institute of Scientific and Technological Research of the State of Amapá---IEPA for the procedures of taxonomic identification and elaboration of exsicatas (sample of pressed species). This was deposited under the number (IAN): 0188.

4.2. Obtaining Essential Oil {#sec4dot2-pharmaceuticals-12-00034}
----------------------------

The essential oil was obtained from the Laboratory of Pharmacognosy and Phytochemistry of the Federal University of Amapá---UNIFAP. The essential oil was obtained by hydrodistillation (temperature 100 °C) in a Clevenger type apparatus for 4 h \[[@B49-pharmaceuticals-12-00034]\].

4.3. Identification of the Chemical Composition of the Essential Oil by Gas Chromatography Coupled to Mass Spectrometry (GC-MS) and Magnetic Nuclear Resonance (NMR) {#sec4dot3-pharmaceuticals-12-00034}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

The analysis of the essential oil was carried out by Gas Chromatography coupled to the Mass Spectrometer (GC-MS) of the Federal University of São Carlos---UFSCar. The Shimadzu equipment, CGEM-SHIMADZU QP 5000, was used. A molten silica capillary column (OPTIMA®-5-0.25 μm), 30 m long and 0.25 mm internal diameter and nitrogen as carrier gas, was used. The operating conditions of the gas chromatograph were: Internal column pressure 67.5 kPa, division ratio 1:20, the gas flow in the column 1.2 mL/min. (210 °C), injector temperature 260 °C, temperature detector or interface (GC-MS) of 280 °C. The initial column temperature was 50 °C, followed by an increase of 6 °C/min. up to 260 °C, this was held constant for 30 min. The mass spectrometer was programmed to perform readings at intervals of 29--400 Da, 0.5 s with ionization energy of 70 eV.

The identification of the chemical compounds present in the essential oil was made from the comparisons of the Linear Indices of Retention (LRI) and Kovats (KI) of the homologous series of n-alkanes (C8--C26) and the literature \[[@B15-pharmaceuticals-12-00034],[@B16-pharmaceuticals-12-00034]\]. In addition to the identification made by combining the spectra obtained by the analysis performed on the equipment and the mass spectra of the software library Labsolutions GC-MS solution version 2.50 SU1.

The structural identification through Nuclear Magnetic Resonance Spectroscopy of Hydrogen 1 and Carbon 13 was developed in the NMR Laboratory of the Department of Chemistry of the Federal University of Amazonas after separation and/or purification of the secondary metabolites of the plant species that compose the essential oils when required.

According to Tavares and Ferreira \[[@B50-pharmaceuticals-12-00034]\], 4--5 mL of Deuterated Chloroform (CDCl~3~) was added in an aliquot of 0.6 mL of the sample. It was inserted to obtain the fids while processing the spectra in a 9.4 T (400 MHz to H), Bruker brand, model DRX400, with a temperature of 300 K, and a 5 mm reverse detection probe. Hydrogen (^1^H) and carbon (^13^C) spectra was also used.

4.4. Analysis of Antioxidant Activity {#sec4dot4-pharmaceuticals-12-00034}
-------------------------------------

The tests performed to evaluate the antioxidant activity (% AA) were carried out at the Laboratory of Pharmacognosy and Phytochemistry of the Federal University of Amapá---UNIFAP. According to the methodology of Sousa et al. \[[@B25-pharmaceuticals-12-00034]\], Lopes-Lutz et al. \[[@B51-pharmaceuticals-12-00034]\] and Andrade et al. \[[@B52-pharmaceuticals-12-00034]\], with adaptations; on the consumption of DPPH.

A methanolic solution of 40 μg·mL^−1^ DPPH was prepared. The essential oil was diluted in methanol at concentrations of 5; 2.5; 1.0; 0.75; 0.50 e 0.25 mg·mL^−1^. For the evaluation, 2.7 mL of DPPH stock solution was added in a test tube, followed by the addition of 0.3 mL of the essential oil solution. The preparation of the negative control was performed from a mixture of 2.7 mL of methanol and the methanolic solution of *T. diversifolia* essential oil. After 30 minutes, spectrophotometric readings (Biospectro SP-22) were performed at 517 nm wavelength \[[@B53-pharmaceuticals-12-00034]\].

The test was performed in triplicate. The antioxidant activity was calculated according to Gulle et al. \[[@B54-pharmaceuticals-12-00034]\]: (%AA) = 100 − {\[(Abs~sample~ − Abs~white~) × 100\] / Abs~control~}%AA = percentage of antioxidant activityAbs~sample~ = Sample AbsorbanceAbs~white~ = Absorbance of whiteAbs~control~ = Control Absorbance

4.5. Cytotoxicity Test {#sec4dot5-pharmaceuticals-12-00034}
----------------------

The cytotoxicity tests against larvae of *A. salina* Leach were carried out in the Laboratory of Pharmacognosy and Phytochemistry of the Federal University of Amapá---UNIFAP. Using the technique of Araújo et al. \[[@B55-pharmaceuticals-12-00034]\] and Lôbo et al. \[[@B56-pharmaceuticals-12-00034]\], with adaptations. First, 250 mL of the 35.5 g·L^−1^ solutions of synthetic sea salt were prepared with 25 mg of *A. salina* eggs exposed to artificial light within 24 h for the hatching of the lavas (methanuplios). Subsequently, these were separated and left in a dark environment, at rest for 24 h to reach the nauplion stage.

Performing the in vitro tests, a stock solution containing 0.06 g of the essential oil, 28.5 mL of the solution of synthetic sea salt and 1.5 mL of dimethylsulfoxide (DMSO) was added. The nauplii were selected and divided into 7 groups with 10 individuals in each test tube. In each group, an aliquot of stock solution was added and the volume was filled to 5 mL with a solution of synthetic sea salt to obtain final solutions with the following concentrations: 1250; 1000; 500; 250; 100; 50 e 10 μg·mL^−1^. Thus, the groups were assigned according to their concentration and all tests were performed in triplicates. In the end, the death toll *A. saline* was recorded to determine LC~50~ by probit analysis using SPSS software version 22, SPSS Inc., Chicago, IL, USA.

4.6. Microbiological Activity {#sec4dot6-pharmaceuticals-12-00034}
-----------------------------

For the evaluation of the antimicrobial activity, the bacteria *Staphylococcus aureus* (ACTC 6538P), *Escherichia coli* (ATCC 8739) and *Pseudomonas aeruginosa* (ATCC 25922) were used. The results were expressed as Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC). MIC was determined by the serial dilution technique in 96-well plates, according to the methodology described in article M07-A10 of 38 manuals \[[@B57-pharmaceuticals-12-00034]\], with adaptations. To obtain the stock solution the polar solvent DMSO was used to aid in the dilution of the essential oil in distilled water. After this step, 50 μL of the *T. diversifolia* essential oil was added to the first well, with a concentration of 200 mg·mL^−1^.

A serial dilution of well A1 to well A12 was performed. Then, 50 μL of the 0.5 turbid inoculum was added to each well, which on the McFarland nephelometric scale is equivalent to 1.5 × 108 CFU/mL in Mueller-Hinton culture medium. The microplates were placed in an oven for 24 h at 35 ± 2 °C.

As a positive control, amoxicillin (50 mg·mL^−1^) was used; for the negative control, a 4% DMSO solution was used to control the culture environment, bacterial growth and turbidity of the essential oil.

The reading was performed on an Elisa microplate reader (Polaris®), after 24 h with absorbances measured at 630 nm. The values obtained were considered for the creation of graphs that express the viability of the microorganisms followed by statistical analysis performed by analysis of variance (ANOVA) with a confidence interval of 99.9%. Significant differences between averages were determined by the Bonferroni test.

For the determination of Minimum Bactericidal Concentration (MBC), Petri dishes containing Mueller-Hinton agar environment were used with the aid of a sterile bacteriological loop, which was inoculated with 10 μL of the suspension contained in the wells that showed no visual growth during experimental MIC. The plates were housed at 35 °C ± 2, MBC was established as the lowest concentration of test substances capable of completely inhibiting the microbial growth in Petri dishes after 24 h of growth.

4.7. Statistical Analysis {#sec4dot7-pharmaceuticals-12-00034}
-------------------------

Statistical analysis was performed using analysis of variance (ANOVA) with a 95% confidence interval. The significant differences between the means were determined by the Tukey test.

5. Conclusions {#sec5-pharmaceuticals-12-00034}
==============

The study based on the essential oil of the species *Tithonia diversifolia* allowed the determination of antioxidant, cytotoxic and antimicrobial activities. The main compounds found in the essential oils of this study were *α-*pinene (9.9%), Limonene (5.40%), *(Z)*-*β*-ocimene (4.02%), *p*-cymen-8-ol (3.0%), Piperitone (11.72%), *(E)*-nerolidol (3.78%) and Spathulenol (10.8%). The antioxidant activity proves that the essential oil of this species has antioxidant action, through the DPPH radical capture method, with IC~50~ of 4.30. Its toxicity was elevated with LC~50~ of 3.11 μg·mL^−1^. For the antimicrobial activity, the samples presented promising results against the bacteria *S. aureus*, *E. coli* and *P. aeruginosa* with inhibition of bacterial growth.
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###### 

Chemical composition of the essential oil of the leaves of *Tithonia diversifolia*.

  N° \*   LRI    KI     Compounds                        Relative Percentage (%)   Identification ^\#^
  ------- ------ ------ -------------------------------- ------------------------- ---------------------
  1       945    939    *α-*pinene                       9.9                       MS, LRI, KI
  2       972    975    Sabinene                         0.85                      MS, IR, KI
  3       982    979    *β-*pinene                       1.34                      MS, IR, KI
  4       1028   1029   Limonene                         5.40                      MS, IR, KI
  5       1032   1037   *(Z)-β*-ocimene                  4.02                      MS, IR, KI
  6       1042   1050   *(E)-β-ocimene*                  0.09                      MS, IR, KI
  7       1069   1070   *CIS-*sabinene hydrate           0.3                       MS, IR, KI
  8       1083   1088   Terpinolene                      0.21                      MS, IR, KI
  9       1090   1091   *p*-cymenene                     0.31                      MS, IR, KI
  10      1099   1096   Linalool                         0.32                      MS, IR, KI
  11      1109   1099   *α-*pinene oxide                 0.33                      MS, IR, KI
  12      1121   1122   *TRANS-*p-mentha-2,8-dien-1-ol   0.35                      MS, IR, KI
  13      1127   1132   (4*E*,6*Z*)-allo-ocimene         1.3                       MS, IR, KI
  14      1135   1137   *CIS-*p-mentha-2,8-dien-1-ol     0.39                      MS, IR, KI
  15      1138   1135   *(Z)-myroxide*                   0.25                      MS, IR, KI
  16      1141   1141   *CIS-*verbenol                   0.43                      MS, IR, KI
  17      1145   1144   *TRANS-*verbenol                 1.68                      MS, IR, KI
  18      1161   1164   *CIS-*Chrysanthenol              0.28                      MS, IR, KI
  19      1171   1169   Borneol                          1.44                      MS, IR, KI
  20      1180   1177   Terpinen-4-ol                    0.31                      MS, IR, KI
  21      1187   1182   *p*-cymen-8-ol                   3.0                       MS, IR, KI
  22      1195   1193   Dihydro carveol                  0.37                      MS, IR, KI
  23      1207   1205   Verbenone                        0.49                      MS, IR, KI
  24      1218   1216   *TRANS-*carveol                  1.0                       MS, IR, KI
  25      1231   1229   *CIS-*carveol                    0.2                       MS, IR, KI
  26      1243   1243   Carvone                          0.42                      MS, IR, KI
  27      1257   1252   Piperitone                       11.72                     MS, IR, KI
  28      1290   1290   Thymol                           0.5                       MS, IR, KI
  29      1298   1299   Carvacrol                        0.57                      MS, IR, KI
  30      1337   1343   Piperitenone                     1.47                      MS, IR, KI
  31      1349   1389   2-Dodecanone                     0.3                       MS, IR, KI
  32      1411   1426   2,5-dimethoxy-p-cymene           0.83                      MS, IR, KI
  33      1417   1466   *(E)-*caryophyllene              0.43                      MS, IR, KI
  34      1477   1488   *(E)-β-i*onone                   0.64                      MS, IR, KI
  35      1489   1493   *α-*zingiberene                  1.21                      MS, IR, KI
  36      1503   1505   *(E,E)-a-*farnesene              0.13                      MS, IR, KI
  37      1563   1563   *(E)-*nerolidol                  3.78                      MS, IR, KI
  38      1578   1578   Spathulenol                      10.8                      MS, IR, KI
  39      1581   1583   Caryophyllene oxide              3.43                      MS, IR, KI
  40      1584   1590   Globulol                         2.64                      MS, IR, KI
  41      1624   1631   *β-*muurola-4,10(14)-dienol      1.8                       MS, IR, KI
  42      1641   1640   epi-*a-*cadinol                  2.04                      MS, IR, KI
  43      1654   1654   *α-*cadinol                      1.35                      MS, IR, KI
  44      1657   1659   Selin-11-en-4-*a*-ol             0.91                      MS, IR, KI
  45      1663   1671   14-hydroxy-*(Z)-*caryophyllene   0.22                      MS, IR, KI
  46      1669   1662   Allohimachalol                   0.82                      MS, IR, KI
  47      1683   1671   Bulnesol                         0.38                      MS, IR, KI
  48      1696   1698   (*2Z,6Z)*-farnesol               0.49                      MS, IR, KI
  49      2106   1943   Phytol                           0.78                      MS, IR, KI
                        Total                            80.26                     

Notes: \* The identification path of the compounds, \# identification of the compounds was performed by the mass spectrum (MS) of the library software Labsolutions GC-MS solution version 2.50 SU1 (NIST05 and WILEY'S Library of Mass spectra 9th Edition); Linear Retention Index (LRI) \[[@B15-pharmaceuticals-12-00034]\] and Kovats Index (KI) \[[@B16-pharmaceuticals-12-00034]\].

pharmaceuticals-12-00034-t002_Table 2

###### 

NMR data of the *α*-pinene substance (S 1) compared to literature data.

  Position   ^1^H NMR         ^1^H NMR \[[@B17-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B17-pharmaceuticals-12-00034]\]
  ---------- ---------------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      1.931            1.931                                          47.05       46.99
  **2**      \-               \-                                             145.06      144.54
  **3**      5.203            5.186                                          116.01      116.10
  **4**      (2.231; 2.210)   2.232                                          31.26       31.25
  **5**      2.065            2.067                                          40.74       40.69
  **6**      \-               \-                                             37.96       37.97
  **7**      (1.616; 1.559)   (1.15; 2.334)                                  31.46       31.45
  **8**      1.282            1.264                                          26.35       26.35
  **9**      0.853            0.834                                          20.80       20.80
  **10**     1.673            1.659                                          22.97       23.01

pharmaceuticals-12-00034-t003_Table 3

###### 

NMR data of the substance Limonene (S 4) compared to literature data.

  Position   ^1^H NMR         ^1^H NMR \[[@B18-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B18-pharmaceuticals-12-00034]\]
  ---------- ---------------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      \-               \-                                             133.62      133.30
  **2**      2.081            2.082                                          27.91       27.90
  **3**      (1.673; 1.495)   (1.675; 1.495)                                 30.59       30.60
  **4**      1.673            1.675                                          41.08       41.10
  **5**      (2.288; 2.081)   (2.289; 2.082)                                 30.80       30.80
  **6**      5.455            5.209                                          120.64      120.70
  **7**      1.791            1.516                                          23.46       23.30
  **8**      \-               \-                                             159.27      149.70
  **9**      1.712            1.558                                          20.67       20.60
  **10**     4.770            (4.952; 4.949)                                 108.35      108.40
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###### 

NMR data of the substance *(Z)-β*-ocimene (S 5) compared to data in the literature.

  Position   ^1^H NMR         ^1^H NMR \[[@B19-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B19-pharmaceuticals-12-00034]\]
  ---------- ---------------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      (4.995; 5.234)   (4.998; 5.233)                                 112.57      112.1
  **2**      6.393            6.395                                          141.16      137.5
  **3**      \-               \-                                             133.74      133.8
  **4**      5.368            5.367                                          133.25      133.1
  **5**      2.471            2.528                                          27.21       27.2
  **6**      5.191            5.189                                          122.3       122.1
  **7**      \-               \-                                             132.02      132.0
  **8**      1.582            1.58                                           21.81       21.8
  **9**      1.749            1.754                                          14.92       15.1
  **10**     1.569            1.58                                           21.81       21.8

pharmaceuticals-12-00034-t005_Table 5

###### 

NMR data of *p*-cymen-8-ol substance (S 21) compared to literature data.

  Position   ^1^H NMR   ^1^H NMR \[[@B19-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B19-pharmaceuticals-12-00034]\]
  ---------- ---------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      \-         \-                                             141.16      139.8
  **2**      7.160      7.104                                          128.87      128.7
  **3**      7.243      7.243                                          124.30      124.3
  **4**      \-         \-                                             150.27      146.3
  **5**      7.243      7.243                                          124.30      124.3
  **6**      7.160      7.104                                          128.87      128.7
  **7**      2.252      2.252                                          21.41       21.3
  **8**      \-         \-                                             70.49       71.4
  **9**      1.382      1.381                                          31.74       31.8
  **10**     1.382      1.381                                          31.74       31.8

pharmaceuticals-12-00034-t006_Table 6

###### 

NMR data of Piperitone substance (S 27) compared to literature data.

  Position   ^1^H NMR         ^1^H NMR \[[@B20-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B20-pharmaceuticals-12-00034]\]
  ---------- ---------------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      \-               \-                                             201.32      200.0
  **2**      5.963            5.951                                          126.83      126.8
  **3**                       \-                                             161.08      161.6
  **4**      (2.296; 2.312)   (2.298; 2.309)                                 30.59       30.5
  **5**      (1.911; 1.846)   (1.910; 1.843)                                 22.97       23.2
  **6**      2.679            2.679                                          51.58       51.6
  **7**      2.186            2.179                                          24.06       24.1
  **8**      1.911            1.910                                          25.83       25.9
  **9**      0.952            0.956                                          20.26       20.1
  **10**     0.952            0.956                                          20.18       20.1
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###### 

NMR data of *(E)-*nerolidol (S 37) substance compared to literature data.

  Position   ^1^H NMR         ^1^H NMR \[[@B21-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B21-pharmaceuticals-12-00034]\]
  ---------- ---------------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      (5.087; 5.017)   (5.085; 5.016)                                 111.65      111.54
  **2**      5.860            5.878                                          144.52      144.86
  **3**      \-               \-                                             70.49       73.01
  **4**      (1.382; 1.623)   (1.388; 1.602)                                 41.74       41.91
  **5**      2.034            2.033                                          22.61       22.61
  **6**      5.277            5.283                                          124.25      124.09
  **7**      \-               \-                                             133.74      134.63
  **8**      1.894            1.894                                          39.65       39.46
  **9**      2.229            2.200                                          26.45       26.41
  **10**     5.287            5.288                                          124.25      124.13
  **11**     \-               \-                                             130.66      130.79
  **12**     1.530            1.538                                          25.66       25.55
  **13**     1.530            1.538                                          16.98       17.33
  **14**     1.604            1.602                                          15.88       15.66
  **15**     1.382            1.388                                          27.37       27.31
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###### 

NMR data of Spathulenol substance (S 38) compared to literature data.

  Position   ^1^H NMR         ^1^H NMR \[[@B22-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B22-pharmaceuticals-12-00034]\]
  ---------- ---------------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      2.384            2.387                                          53.40       53.37
  **2**      (1.996; 1.681)   (1.996; 1.686)                                 26.67       26.68
  **3**      (1.530; 1.771)   (1.538; 1.778)                                 41.74       41.71
  **4**      \-               \-                                             80.99       80.90
  **5**      1.530            1.538                                          54.33       54.27
  **6**      0.853            0.837                                          29.92       29.90
  **7**      0.912            0.912                                          27.46       27.46
  **8**      (1.530; 1.521)   (1.538; 1.522)                                 24.78       24.74
  **9**      (2.380; 2.384)   (2.381; 2.387)                                 38.86       38.83
  **10**     \-               \-                                             153.43      153.38
  **11**     \-               \-                                             20.18       20.21
  **12**     1.141            1.143                                          28.65       28.62
  **13**     1.141            1.143                                          16.32       16.29
  **14**     (4.875; 5.065)   (4.861; 5.061)                                 28.7        28.65
  **15**     1.327            1.329                                          106.25      106.22
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###### 

NMR data of Caryophyllene oxide (S 39) compared to literature data.

  Position   ^1^H NMR       ^1^H NMR \[[@B23-pharmaceuticals-12-00034]\]   ^13^C NMR   ^13^C NMR \[[@B23-pharmaceuticals-12-00034]\]
  ---------- -------------- ---------------------------------------------- ----------- -----------------------------------------------
  **1**      1.73           1.76                                           50.7        50.9
  **2**      (1.57; 1.63)   (1.45; 1.63)                                   27.9        27.2
  **3**      (0.94; 2.03)   (0.95; 2,06)                                   39.1        39.2
  **4**      \-             \-                                             54.3        59.6
  **5**      2.85           2.86                                           6.37        63.6
  **6**      (1.28; 2.29)   (1.28; 2.23)                                   30.1        30.1
  **7**      (2.16; 2.85)   (2.11; 2.37)                                   29.8        29.8
  **8**      \-             \-                                             150.2       151.7
  **9**      (2.85)         2.60                                           48.7        48.7
  **10**     (1.43; 1.48)   (1.43; 1.47)                                   39.7        39.8
  **11**     \-             \-                                             33.5        33.9
  **12**     (4.80; 4.97)   (4.81; 4.99)                                   16.9        16.9
  **13**     1.20           1.19                                           112.7       112.7
  **14**     (0.98; 1.00)   (0.98; 1.01)                                   29.8        29.8
  **15**     (0.98; 1.00)   (0.98; 1.01)                                   20.8        21.6
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###### 

%AA values of the essential oil of the leaves of *T. diversifolia*.

                          Concentration (mg·mL^−1^)                                                                                               
  ----------------------- --------------------------- ----------------- ----------------- ----------------- ------------------ ------------------ --------
  **Plant species**       5                           2.5               1                 0.75              0.5                0.25               IC~50~
  ***T. diversifolia***   54.6 ± 0.06 ^a^             37.4 ± 0.27 ^b^   27.4 ± 0.41 ^c^   23.9 ± 0.55 ^d^   21.8 ± 0.13 ^eg^   20.2 ± 0.79 ^fg^   4.30
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###### 

\% AA values of the Ascorbic acid.

                        Concentration (µg·mL^−1^)                                                                         
  --------------------- --------------------------- ------------- ------------- -------------- ----------- -------------- --------
  **compound**          250                         125           62.5          31.25          15.62       7.81           IC~50~
  ***Ascorbic acid***   99.99 ± 0.0                 99.99 ± 0.0   99.99 ± 0.0   99.93 ± 0.02   30 ± 0.10   18.57 ± 0.52   16.71
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###### 

Mortality of *A. salina* larvae at different concentrations of *T. diversifolia* essential oil.

                          Concentration (µg·mL^−1^)                                                                 
  ----------------------- --------------------------- --------- --------- --------- --------- ---------- ---------- --------
  **Plant species**       1250                        1000      500       250       100       50         10         LC~50~
  ***T. diversifolia***   100 ^a^                     100 ^a^   100 ^a^   100 ^a^   100 ^a^   98.1 ^b^   83.5 ^c^   3.11

pharmaceuticals-12-00034-t013_Table 13

###### 

Minimum Inhibitory Concentration (MIC) of OE *T. diversifolia*.

  Plant Species *T. diversifolia*                  
  --------------------------------- ---- ---- ---- ----
  *Staphylococcus aureus*           \+   \+   NA   NA
  *Escherichia coli*                \+   \+   \+   \+
  *Pseudomonas aeruginosa*          \+   \+   NA   NA
  Amoxicillin (Positive Control)    \+   \+   \+   \+
  DMSO (Negative control)           NA   NA   NA   NA

NA: it did not show.
